Cell Culture Modeling of Genotype-Directed Sensitivity to Selective Kinase Inhibitors: Targeting the Anaplastic Lymphoma Kinase (ALK)

Seminars in Oncology

Volumn 36, Issue SUPPL. 1, 2009, Pages

  Settleman, Jeff ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; SUNITINIB; TAE 684; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADDICTION; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL TUMOR; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; ONCOGENE ADDICTION; PATIENT CARE; PRIORITY JOURNAL; TREATMENT RESPONSE;

CELLS, CULTURED; DRUG DESIGN; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 64849101672     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.02.006     Document Type: Article

References (32)

1. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 (1998) 2659-2671
2. Pegram M.D., Pauletti G., and Slamon D.J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52 (1998) 65-77
3. Baselga J., Albanell J., Molina M.A., and Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 28 (2001) 4-11
4. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1 (2002) 31-36
5. Joensuu H., Fletcher C., Dimitrijevic S., Silberman S., Roberts P., and Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3 (2002) 655-664
6. Sequist L.V., Bell D.W., Lynch T.J., and Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007) 587-595
7. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
8. Sharma S.V., and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21 (2007) 3214-3231
9. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
10. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
11. Lin W.M., Baker A.C., Beroukhim R., Winckler W., Feng W., Marmion J.M., et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68 (2008) 664-673
12. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006) 515-527
13. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 (2007) 893-898
14. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104 (2007) 19936-19941
15. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103 (2006) 2316-2321
16. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
17. Chiarle R., Voena C., Ambrogio C., Piva R., and Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8 (2008) 11-23
18. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
19. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14 (2008) 4275-4283
20. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455 (2008) 971-974
21. Caren H., Abel F., Kogner P., and Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416 (2008) 153-159
22. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 (2008) 975-978
23. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455 (2008) 967-970
24. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (2008) 930-935
25. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68 (2008) 3389-3395
26. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
27. Fong T., Morgensztern D., and Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 303-310
28. Chang J.W., Liu H.P., Hsieh M.H., Fang Y.F., Hsieh M.S., Hsieh J.J., et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer 61 (2008) 328-339
29. Kwak E.L., Jankowski J., Thayer S.P., Lauwers G.Y., Brannigan B.W., Harris P.L., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12 (2006) 4283-4287
30. Steffensen K.D., Waldstrom M., Olsen D.A., Corydon T., Lorentzen K.A., Knudsen H.J., et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 14 (2008) 3278-3282
31. Vermeij J., Teugels E., Bourgain C., Xiangming J., in′ V., Ghislain V., et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 8 (2008) 3
32. Kimura T., Maesawa C., Ikeda K., Wakabayashi G., and Masuda T. Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol Rep 15 (2006) 1205-1210